TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN) announced today results from recently completed studies that further demonstrate the therapeutic potential of CGEN-928 as a drug target for treatment of multiple myeloma (MM) through mAb therapy. These new studies were carried out by the Institute for Myeloma & Bone Cancer Research (IMBCR) and are being presented at the 52nd American Society of Hematology (ASH) now taking place in Orlando, FL.
